checkAd

     151  0 Kommentare Roche launches Elecsys Epstein-Barr Virus (EBV) immunoassay panel to improve EBV infection staging - Seite 3

    This further addition to the Roche EBV testing portfolio follows on from the announcement of the CE Mark and FDA authorisation for the first Epstein-Barr virus quantitative test on the cobas 6800/8800 Systems to improve care for transplant patients.

    About Roche
    Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

    Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management.

    Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. More than thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Moreover, for the twelfth consecutive year, Roche has been recognised as one of the most sustainable companies in the Pharmaceuticals Industry by the Dow Jones Sustainability Indices (DJSI).

    The Roche Group, headquartered in Basel, Switzerland, is active in over 100 countries and in 2020 employed more than 100,000 people worldwide. In 2020, Roche invested CHF 12.2 billion in R&D and posted sales of CHF 58.3 billion. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit www.roche.com.

    All trademarks used or mentioned in this release are protected by law.

    References
    [1] Balfour HH, Jr, et al..  J Infec Dis. 2013;208(8):1286-93.
    [2] Dudley et al. Nephron Clin Prac (2011) 118 Suppl 1:c209-24 , 
    [3] EDQM. 7th edition.
    [4] Padalko et al, Cell Tissue Bank (2018;)19(4):681-95,
    [5] Nowalk A and Green M.. Microbiol Spectr. 2016;4(3).
    [6] De Paschale and Clerici World J Virol. 2012;1(1):31-43,
    [7] Niller HH and Bauer G. Methods in Molecular Biology; 2017.
    [8] Klutts et al. J ClinMicrobiol , 2009 :81(2):325-331.

    Seite 3 von 4



    Diskutieren Sie über die enthaltenen Werte



    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Roche launches Elecsys Epstein-Barr Virus (EBV) immunoassay panel to improve EBV infection staging - Seite 3 The Elecsys EBV panel accurately identifies the EBV infection stage from a single blood sample, which means less confirmatory testing and, potentially, faster diagnosis for patientsClear and quick diagnosis of acute infection allows physicians to …

    Schreibe Deinen Kommentar

    Disclaimer